Ilan Ganot is the CEO and co-founder of Solid Biosciences Inc., a company focused on improving treatments for Duchenne Muscular Dystrophy (DMD). He has a strong background in finance and has held key positions at major banks like JPMorgan Chase...

Ilan Ganot is the CEO and co-founder of Solid Biosciences Inc., a company focused on improving treatments for Duchenne Muscular Dystrophy (DMD). He has a strong background in finance and has held key positions at major banks like JPMorgan Chase and Lehman Brothers before launching Solid Biosciences. Ganot has been involved with the company since its inception in 2013 and became the President in 2018. He studied at London Business School and has law and business degrees from the Interdisciplinary Center in Herzliya, Israel. In addition to his business skills, he served as a Captain in the Israeli Defense Forces, showing his leadership ability early on. Under his direction, Solid has made strides in clinical trials and development of potential therapies for DMD. In 2022, his total compensation was reported at about $2.576 million, highlighting the company’s growth and his role in it. He is intensely focused on improving the quality of life for patients with DMD, which drives the company's mission and his leadership style.